5. The pharmaceutical combination according to claim 1, wherein the Bcl2 inhibitor is navitoclax, or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical combination according to claim 1 comprising the MEK inhibitor and the Bcl2 inhibitor.

7. The pharmaceutical combination according to claim 1, wherein the combination further comprises an EGFR inhibitor.

8. The pharmaceutical combination according to claim 7, wherein the EGFR inhibitor is selected from the group consisting of erlotinib, gefitinib, lapatinib, canertinib, pelitinib, neratinib, (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino) but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide, panitumumab, matuzumab, pertuzumab, nimotuzumab, zalutumumab, icotinib, afatinib and cetuximab, and pharmaceutically acceptable salt thereof.

9. The pharmaceutical combination according to claim 7, wherein the EGFR inhibitor is erlotinib, or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical combination according to claim 1, wherein the combination further comprises a PI3K inhibitor.

11. The pharmaceutical combination according to claim 10, wherein the PI3K inhibitor is selected from the group consisting of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, and (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof.

12. The pharmaceutical combination according to claim 10, wherein the PI3K inhibitor is an alpha-isoform specific phosphatidylinositol-3-kinase (PI3K) inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or any pharmaceutically acceptable salt thereof.

13. The pharmaceutical combination according to claim 1, wherein the combination further comprises a BRAF inhibitor.

14. The pharmaceutical combination according to claim 13, wherein the BRAF inhibitor is selected from the group consisting of RAF265, dabrafenib, (S)-methyl-1-(4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate, methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate and vemurafenib, or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical combination according to claim 13, wherein the BRAF inhibitor is dabrafenib, or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical combination according to claim 1, wherein the combination further comprises a CD4/6 inhibitor.

17. The pharmaceutical combination according to claim 16, wherein the CD4/6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxamide, or pharmaceutically acceptable salt thereof.

18. The pharmaceutical combination according to claim 1, wherein the combination further comprises paclitaxel.

19. The pharmaceutical combination according to claim 13, wherein the combination further comprises a cMET inhibitor.

20. The pharmaceutical combination according to claim 19, wherein the cMET inhibitor is PF-04217903.

21. The pharmaceutical combination according to claim 1 for simultaneous or sequential use.

22. The pharmaceutical combination according to claim 1 in the form of a fixed combination.

23. The pharmaceutical combination according to claim 1 in the form of a non-fixed combination.

24. A pharmaceutical composition comprising the pharmaceutical combination according to claim 1 and at least one pharmaceutically acceptable carrier.

25. (canceled)

26. The pharmaceutical combination according to claim 1, for the treatment of a cancer.

27. (canceled)

28. A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination according to claim 1.

29. The pharmaceutical combination according to claim 26, wherein the cancer is a solid tumor.

30. The pharmaceutical combination according to claim 26, wherein the cancer is selected from the group consisting of a benign or malignant tumor of the lung, small cell lung cancer, non-small cell lung cancer, bronchus, prostate, breast, sporadic breast cancers, Cowden disease, pancreas, gastrointestinal tract, colon, rectum, colon carcinoma, colorectal cancer, thyroid, liver, biliary tract, intrahepatic bile duct, hepatocellular, adrenal gland, stomach, gastric, glioma, glioblastoma, endometrial, kidney, renal pelvis, bladder, uterus, cervix, vagina, ovary, multiple myeloma, esophagus, neck or head, brain, oral cavity and pharynx, larynx, small intestine, a melanoma, villous colon adenoma, a sarcoma, a neoplasia, a neoplasia of epithelial character, a mammary carcinoma, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, polycythemia vera, essential thrombocythemia, a leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, lymphocytic leukemia, myeloid leukemia, a lymphoma, non-Hodgkin lymphoma and Hodgkin's lymphoma, myelofibrosis with myeloid metaplasia, Waldenstroem disease, and Barret's adenocarcinoma.

31. The pharmaceutical combination according to claim 26, wherein the cancer is a colorectal cancer, liposarcoma, glioblastoma, neuroblastoma, lymphoma, leukemia or melanoma.

32. The pharmaceutical combination according to claim 31, wherein the cancer is colorectal cancer.

33. The pharmaceutical combination according to claim 26, wherein the cancer is a metastatic colorectal cancer.

34. The pharmaceutical combination according to claim 26, wherein the cancer comprises functional p53 or wild-type TP53.

35. The pharmaceutical combination according to claim 26 wherein the cancer comprises one or more of KRAS mutation and/or BRAF mutation and/or MEK1 mutation and/or PIK3CA mutation and/or PIK3CA overexpression.

36. The pharmaceutical combination according to claim 26, wherein the cancer comprises one or more of KRAS mutation.